U.S. Markets open in 7 hrs, 20 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,384.21 | 152.25 | 1.36% |
| NASDAQ | 2,294.44 | 51.12 | 2.28% |
| S&P 500 | 1,273.70 | 21.39 | 1.71% |
| Day Low 09:40 AM EDT | 76.26 | |
|---|---|---|
| Day High 11:59 AM EDT | 78.45 |
|
| Range | 2.19 | |
| Volume | 4.75 M | |
| 30-Day Avg. Vol. | 3.38 M |
|
| Difference | 40.64% | |
| Market Cap. | 81.87 B | |
| Change | 2.08 B | |
| Shares Out. | 1.05 B | |
| Percent Traded | 0.45% | |
| Revenue | 11.72 B | |
| Earnings | 2.76 B | |
| EPS (TTM) | 2.85 |
| 52-Wk Low 12/6/07 | 65.35 | |
|---|---|---|
| 52-Wk High 3/26/08 | 82.20 |
|
| Range | 16.85 | |
| Prev. Close 7/7/08 | 75.93 | |
| Today's Open | 76.84 | |
| Change | 1.20% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 0.6847 | |
| P/E Ratio (TTM) | 27.34 | |
| P/E Ratio (Fwd.) | 22.00 |
"The few, the proud, the profitable" could be Genentech's motto. One of the world's most successful biotechs (in an industry full of money-losers), the firm has three billion-dollar blockbusters: Rituxan, ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | 0.674 12/31/07 | 0.69 12/31/07 |
0.016
Beat
|
| Last Quarter | 0.821 3/31/08 | 0.84 3/31/08 |
0.019
Beat
|
| Quarterly - 03/31/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 3.06 B | 11.72 B |
| Gross Profit | 2.67 B | 10.15 B |
| Operating Income | 1.82 B | 4.24 B |
| Net Income | 983.00 M | 2.77 B |
